Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 27, 2024
Data Byte
Junshi’s PD-1 among seven new products recommended by EMA’s CHMP
Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions
BioCentury | Jul 30, 2022
Data Byte
Assessing an expanse of ALS targets
Restoring neurotransmission may be the key to slowing fatal disease
BioCentury | Dec 23, 2021
Product Development
First-in-class drugs fill FDA’s 2021 class of new approvals
Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
BioCentury | Dec 11, 2021
Discovery & Translation
New targets at ASH hint at an emerging T cell cancer focus
BioCentury’s ASH21 analysis identifies 22 new targets spanning seven mechanistic categories
BioCentury | Apr 16, 2021
Targets & Mechanisms
New targets featured at AACR signal growing opportunity in established mechanisms
Protein degraders, ion channel regulators and novel checkpoints are among new targets presented at AACR21
BioCentury | Jan 24, 2021
Regulation
Lupus nephritis patients gain oral option as FDA approves Aurinia’s Lupkynis
Inclusion of dosing program in label could extend patent coverage
BioCentury | Jul 24, 2020
Product Development
July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit
BioCentury | Jun 4, 2020
Product Development
With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment
The BLyS inhibitor could become the first drug for lupus nephritis, which affects about 1 million patients
BioCentury | Apr 30, 2020
Management Tracks
Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more
BioCentury | Mar 7, 2020
Emerging Company Profile
Kira: depleting activated dendritic cells
Kira aims to deplete activated dendritic cells for GvHD and autoimmune disease
Items per page:
1 - 10 of 233